Literature DB >> 12109858

Clinicopathologic significance of expression of CD44s and CD44v6 isoforms in squamous cell carcinoma of the supraglottic larynx.

Juan P Rodrigo1, Francisco Domínguez, Cesar Alvarez, María V González, Agustín Herrero, Carlos Suárez.   

Abstract

CD44 splice variants are assumed to have a critical role in the malignant progression of many human tumors. However, the clinical significance of CD44 expression is not yet understood. The aim of this study was to investigate the prognostic significance of expression of CD44s and CD44v6 isoforms in squamous cell carcinomas of the supraglottic larynx. CD44s and CD44v6 expression was determined by immunohistochemical analysis of paraffin-embedded tissue specimens from 101 patients. There was a significant correlation between decreased CD44s or CD44v6 expression and a poorer histologic differentiation. No relationship was observed with T stage or nodal metastasis. Decreased CD44s expression, but not CD44v6 expression, correlated with increased recurrence rates. There was no correlation between the decreased expression of any isoform tested and survival. These data confirm a reduction of CD44s and CD44v6 expression in poorly differentiated tumors. However, these changes do not offer a useful adjunct to current prognostic indicators.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12109858     DOI: 10.1309/F50H-6MLG-R7LM-2XFT

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  13 in total

1.  Significance of immunohistochemical over-expression of CD44v6 as an indicator of malignant potential in esophageal squamous cell carcinoma.

Authors:  T Nozoe; S Kohnoe; T Ezaki; A Kabashima; Y Maehara
Journal:  J Cancer Res Clin Oncol       Date:  2004-02-11       Impact factor: 4.553

2.  Expression and association of CD44v6 with prognosis in T2-3N0M0 esophageal squamous cell carcinoma.

Authors:  Han Yang; Junling Liu; Hui Yu; Peng Sun; Yi Hu; Jiudi Zhong; Zhihua Zhu
Journal:  J Thorac Dis       Date:  2014-02       Impact factor: 2.895

3.  CD44 expression in oro-pharyngeal carcinoma tissues and cell lines.

Authors:  Abirami Rajarajan; Angela Stokes; Balvinder K Bloor; Rebecca Ceder; Hemini Desai; Roland C Grafström; Edward W Odell
Journal:  PLoS One       Date:  2012-01-05       Impact factor: 3.240

Review 4.  The role of CD44 in epithelial-mesenchymal transition and cancer development.

Authors:  Hanxiao Xu; Yijun Tian; Xun Yuan; Hua Wu; Qian Liu; Richard G Pestell; Kongming Wu
Journal:  Onco Targets Ther       Date:  2015-12-16       Impact factor: 4.147

5.  Expression of COX-2, CD44v6 and CD147 and relationship with invasion and lymph node metastasis in hypopharyngeal squamous cell carcinoma.

Authors:  Qing Yang; Yehai Liu; Yang Huang; Dake Huang; Yifan Li; Jing Wu; Maoli Duan
Journal:  PLoS One       Date:  2013-09-03       Impact factor: 3.240

6.  Detection of high CD44 expression in oral cancers using the novel monoclonal antibody, C44Mab-5.

Authors:  Shinji Yamada; Shunsuke Itai; Takuro Nakamura; Miyuki Yanaka; Mika K Kaneko; Yukinari Kato
Journal:  Biochem Biophys Rep       Date:  2018-04-12

7.  Role of CD44 as a marker of cancer stem cells in head and neck cancer.

Authors:  Serena Trapasso; Eugenia Allegra
Journal:  Biologics       Date:  2012-11-01

8.  Cancer stem cells in head and neck cancer.

Authors:  Eugenia Allegra; Serena Trapasso
Journal:  Onco Targets Ther       Date:  2012-11-21       Impact factor: 4.147

Review 9.  Prognostic value of CD44 expression in renal cell carcinoma: a systematic review and meta-analysis.

Authors:  Xintao Li; Xin Ma; Luyao Chen; Liangyou Gu; Yu Zhang; Fan Zhang; Yun Ouyang; Yu Gao; Qingbo Huang; Xu Zhang
Journal:  Sci Rep       Date:  2015-08-19       Impact factor: 4.379

10.  Targeting CD44v6 for fluorescence-guided surgery in head and neck squamous cell carcinoma.

Authors:  Julia Odenthal; Mark Rijpkema; Desirée Bos; Esther Wagena; Huib Croes; Reidar Grenman; Otto Boerman; Robert Takes; Peter Friedl
Journal:  Sci Rep       Date:  2018-07-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.